TRANSFORMING a standard truck into an off road monster has been a passion project for one man and his team of genius engineers. Gregg Higgs is owner of Fab Fours, a car accessory manufacturer that has ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday. As part of the ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi.

Gilead to pay Kymera up to $750 million for CDK2 degrader program; upfront and option payments total up to $85 million. PPI and Industrial Production drop Wednesday morning — see how Matt Maley ...

Kymera is selling 5,044,500 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 655,500 shares of common stock in the offering.

Kymera Therapeutics reported that an experimental drug designed to rival Sanofi and Regeneron’s blockbuster therapy Dupixent succeeded in a closely watched early-stage trial.